A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
Hsu CR, Chen YH, Liu CP, Chen CH, Huang KK, Huang JW, Lin MN, Lin CL, Chen WR, Hsu YL, Lee TC, Chou SH, Tu CM, Hwang CS, Huang YC, Lu DW.
Hsu CR, et al. Among authors: huang kk, huang jw, huang yc.
Invest Ophthalmol Vis Sci. 2019 Feb 1;60(2):624-633. doi: 10.1167/iovs.18-25252.
Invest Ophthalmol Vis Sci. 2019.
PMID: 30735565